caribou biosciences is a leading biotechnology company in genome engineering. we develop technology-based solutions for cellular engineering and analysis based on the crispr-cas9 technology platform. cas9, when paired with a guide rna, cuts double-stranded dna allowing for specific changes to dna. these site-specific dna modifications can be utilized to carry out sophisticated gene knock-outs or knock-ins. caribou's technologies mark a revolutionary development that allows scientists to engineer nearly any part of any genome with extreme flexibility. forbes magazine has called cas9 the protein that "could change biotech forever" and the new york times has noted that "the pace of new discoveries and applications is dizzying." caribou's tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. interested in joining our team? please contact us at jobs at cariboub
Company profile
Ticker
CRBU
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Antler Holdco, LLC • Arboreal Holdco, LLC • Biloba Holdco, LLC • Microbe Holdco, LLC ...
IRS number
453728228
CRBU stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
7 May 24
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
8-K
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
4 Apr 24
S-8
Registration of securities for employees
11 Mar 24
10-K
2023 FY
Annual report
11 Mar 24
8-K
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
11 Mar 24
8-K
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
8 Jan 24
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 49.45 mm | 49.45 mm | 49.45 mm | 49.45 mm | 49.45 mm | 49.45 mm |
Cash burn (monthly) | 587.33 k | 278.67 k | 15.33 mm | 10.91 mm | 12.40 mm | 8.55 mm |
Cash used (since last report) | 986.45 k | 468.03 k | 25.75 mm | 18.33 mm | 20.83 mm | 14.35 mm |
Cash remaining | 48.46 mm | 48.98 mm | 23.69 mm | 31.12 mm | 28.62 mm | 35.09 mm |
Runway (months of cash) | 82.5 | 175.8 | 1.5 | 2.9 | 2.3 | 4.1 |
Institutional ownership, Q4 2023
22.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 24 |
Opened positions | 7 |
Closed positions | 112 |
Increased positions | 3 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 16.55 bn |
Total shares | 20.02 mm |
Total puts | 200.00 |
Total calls | 400.00 |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Avidity Partners Management | 6.36 mm | $36.44 mm |
PFE Pfizer | 4.69 mm | $19.93 mm |
Rachel E. Haurwitz | 3.35 mm | $37.21 mm |
Farallon Capital Partners | 2.58 mm | $41.11 mm |
Assenagon Asset Management | 2.26 mm | $12.94 bn |
Mirae Asset Global Investments | 173.61 k | $994.76 mm |
DekaBank Deutsche Girozentrale | 130.00 k | $764.00 k |
Raymond James & Associates | 114.86 k | $658.17 mm |
Nelson Roberts Investment Advisors | 85.02 k | $487.17 mm |
Green Alpha Advisors | 79.56 k | $455.90 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Feb 24 | Jason O'Byrne | Common Stock | Grant | Acquire A | No | No | 0 | 33,000 | 0.00 | 59,224 |
20 Feb 24 | Jason O'Byrne | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 6.81 | 153,000 | 1.04 mm | 153,000 |
20 Feb 24 | Barbara G Mcclung | Common Stock | Grant | Acquire A | No | No | 0 | 33,000 | 0.00 | 409,566 |
20 Feb 24 | Barbara G Mcclung | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 6.81 | 153,000 | 1.04 mm | 153,000 |
20 Feb 24 | Ruhi Ahmad Khan | Common Stock | Grant | Acquire A | No | No | 0 | 33,000 | 0.00 | 33,000 |
20 Feb 24 | Ruhi Ahmad Khan | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 6.81 | 153,000 | 1.04 mm | 153,000 |
20 Feb 24 | Rachel E. Haurwitz | Common Stock | Grant | Acquire A | No | No | 0 | 118,700 | 0.00 | 158,700 |
20 Feb 24 | Rachel E. Haurwitz | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 6.81 | 546,950 | 3.72 mm | 546,950 |
20 Feb 24 | Steven Kanner | Common Stock | Grant | Acquire A | No | No | 0 | 33,000 | 0.00 | 387,037 |
20 Feb 24 | Steven Kanner | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 6.81 | 153,000 | 1.04 mm | 153,000 |
News
Attention Biotech Investors - Stocks To Watch From RBC Global Healthcare Conference
16 May 24
Expert Ratings For Caribou Biosciences
16 May 24
Truist Securities Maintains Buy on Caribou Biosciences, Maintains $19 Price Target
16 May 24
HC Wainwright & Co. Reiterates Buy on Caribou Biosciences, Maintains $24 Price Target
13 May 24
Caribou Biosciences Q1 EPS $(0.46) Misses $(0.40) Estimate, Sales $2.43M Miss $2.90M Estimate
7 May 24
Press releases
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
13 May 24
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
27 Apr 24
Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
15 Apr 24
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
4 Apr 24
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
27 Mar 24